Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings Plc, a developer of novel immunotherapies for cancer, is set to present significant clinical data at the 21st CIMT Annual Meeting in Mainz, Germany. The company will showcase an oral presentation on its DNA plasmid melanoma cancer vaccine, SCIB1, as well as poster presentations on T cell receptor isolation and CAR-T cell therapy targeting gastrointestinal tumors. These presentations underscore Scancell’s commitment to advancing cancer treatment through its proprietary technology platforms.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
